Andrew Oxtoby insider trades: Aimmune Therapeutics (AIMT) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Andrew reports to the SEC
Open-market buys and sales
1 trade reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Mar 13, 2020 | AIMT | ↑ Buy | 3,000 | $14.76 | $44K | Direct | Mar 17, 2020 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Andrew Oxtoby's insider trades
Andrew Oxtoby is Chief Commercial Officer at Aimmune Therapeutics (AIMT). Since Mar 13, 2020, Andrew has reported 1 open-market purchase worth $44K and no sales on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), shares returned to the company (2 filings), shares withheld for taxes (2 filings), other transactions (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AIMT insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.